Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.58 |
| ▸ | AKT1 | P31749 | 10/20 | 0.53 |
| ▸ | AKT2 | P31751 | 10/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21500652 | 0.89 | F2RL1 (0.56) | F2RL1AKT1AKT2NPC1RAB9A | |
| SCHEMBL15050025 | 0.86 | AKT1 (0.58) | F2RL1AKT1AKT2NPC1RAB9A | |
| SCHEMBL15071104 | 0.83 | HPGD (0.52) | F2RL1AKT1AKT2NPC1RAB9A | |
| SCHEMBL15071152 | 0.83 | F2RL1 (0.75) | F2RL1 | |
| SCHEMBL7467961 | 0.82 | AKT1 (0.56) | F2RL1AKT1AKT2AKR1B1 | |
| SCHEMBL15071100 | 0.82 | F2RL1 (0.77) | F2RL1AKT1AKT2NPC1RAB9A | |
| SCHEMBL31518 | 0.81 | F2RL1 (0.72) | F2RL1AKT1AKT2 | |
| SCHEMBL15071143 | 0.80 | F2RL1 (0.74) | F2RL1AKT1AKT2NPC1RAB9A | |
| SCHEMBL15050009 | 0.80 | F2RL1 (0.68) | F2RL1AKT1AKT2 | |
| SCHEMBL12920734 | 0.80 | COMT (0.55) | F2RL1AKT1AKT2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2617721-A2 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | Neopharm Co., Ltd. (KR) | 2013-07-24 | — | — | EP | disclosed |
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO.,LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| WO-2012026765-A2 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | (주)네오팜 (KR) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | F2RL1, F2R, FPR2 | F2RL1 1/4885AKT1 669/4885AKT2 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.